Leonie Prince
Child & Adolescent Psychiatry · Marlton, NJNPI 1922218569
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.2% of the total across 377 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 37.3% of the total. 2025 is the largest year on record at $1,662, 4.7 times the $357 reported in 2019.
Across 377 payments — averaging $11.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$965
- Alkermes, Inc.$721
- Otsuka America Pharmaceutical, Inc.$379
- E.r. Squibb & Sons, L.L.C.$183
- Lundbeck LLC$135
- plus $343 from 7 others
What the payments were for
- Food & beverage$4,05093%
- Education$2947%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 165 | $1,619 |
| Neurocrine Biosciences, Inc. | 101 | $965 |
| Alkermes, Inc. | 40 | $721 |
| Otsuka America Pharmaceutical, Inc. | 18 | $379 |
| E.r. Squibb & Sons, L.L.C. | 19 | $183 |
| Lundbeck LLC | 9 | $135 |
| Sunovion Pharmaceuticals Inc. | 9 | $99 |
| Johnson & Johnson | 6 | $90 |
| Almatica Pharma LLC | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $41 |
| Vanda Pharmaceuticals Inc. | 3 | $36 |
| AbbVie | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$500
- AUSTEDO$235
- INGREZZA$125
- Austedo XR$118
- ABILIFY ASIMTUFII$103
- ABILIFY MAINTENA$103
How this compares
$4,344 in reported general payments places this provider in the 85th percentile of 137 child & adolescent psychiatry providers in New Jersey.
See all child & adolescent psychiatry providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 34 | $311,896 |
| AustedoDeutetrabenazine | 34 | $254,569 |
| IngrezzaValbenazine Tosylate | 38 | $124,844 |
| Invega SustennaPaliperidone Palmitate | 35 | $109,139 |
| Clozapine | 272 | $23,937 |
| FanaptIloperidone | 32 | $13,674 |
| Lurasidone Hcl | 15 | $7,693 |
| QuviviqDaridorexant Hcl | 13 | $6,019 |
| Fluphenazine Hcl | 30 | $5,580 |
| Aripiprazole | 105 | $5,516 |
| Divalproex Sodium ErDivalproex Sodium | 70 | $4,669 |
| Fluphenazine Decanoate | 22 | $3,844 |
| Asenapine Maleate | 22 | $3,631 |
| Bupropion XlBupropion Hcl | 153 | $3,207 |
| Paliperidone ErPaliperidone | 89 | $2,890 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $1,619 | $566,46568 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $965 | $124,84438 claims |
| Johnson & JohnsonInvega Sustenna | $90 | $109,13935 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $36 | $13,67432 claims |
| Almatica Pharma LLCSertraline Hcl | $45 | $541110 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 137 child & adolescent psychiatry providers in New Jersey.
Other child & adolescent psychiatry in Marlton
- Alexander StraussMarlton$2K
- Ravinder BhallaRidgewood$125K
- Steven DyckmanEast Brunswick$53K
- Eric BartkyLivingston$51K
- Bohdan CzartoryskyParsippany$21K
- Akhtar HossainSomerville$19K
- Suzanne LindNew Brunswick$18K
- Aykut OzdenEdgewater$17K
- Valeria KorshunovaHackensack$12K
- Carol DobrzynskiBrick$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.